Search

Your search keyword '"Pavlidis, Stelios"' showing total 2 results
Start Over Author "Pavlidis, Stelios" Language undetermined
2 results on '"Pavlidis, Stelios"'

1. Clinical and transcriptomic features of persistent exacerbation-prone severe asthma in U-BIOPRED cohort

Author

Hoda, Uruj, Pavlidis, Stelios, Bansal, Aruna T, Takahashi, Kentaro, Hu, Sile, Ng Kee Kwong, Francois, Rossios, Christos, Sun, Kai, Bhavsar, Pankaj, Loza, Matthew, Baribaud, Frederic, Chanez, Pascal, Fowler, Stephen J, Horvath, Ildiko, Montuschi, Paolo, Singer, Florian, Musial, Jacek, Dahlen, Barbro, Krug, Norbert, Sandstrom, Thomas, Shaw, Dominic E, Lutter, Rene, Fleming, Louise J, Howarth, Peter H, Caruso, Massimo, Sousa, Ana R, Corfield, Julie, Auffray, Charles, De Meulder, Bertrand, Lefaudeux, Diane, Dahlen, Sven-Erik, Djukanovic, Ratko, Sterk, Peter J, Guo, Yike, Adcock, Ian M, Chung, Kian Fan, Pulmonology, AII - Inflammatory diseases, and Commission of the European Communities

Subjects
severe asthma, Bronchi/pathology, Medicine (miscellaneous), PHENOTYPES, 1110 Nursing, 610 Medicine & health, Bronchi, Research & Experimental Medicine, Sputum/metabolism, Cohort Studies, Humans, CEACAM5, Asthma/genetics, Science & Technology, STATEMENT, Sputum, Transcriptome/genetics, Asthma, frequent exacerbators, Oncology, Medicine, Research & Experimental, asthma exacerbations, Molecular Medicine, U-BIOPRED study group, 610 Medizin und Gesundheit, Transcriptome, Life Sciences & Biomedicine, persistent frequent exacerbators, LUNG
Abstract

BACKGROUND: Exacerbation-prone asthma is a feature of severe disease. However, the basis for its persistency remains unclear.OBJECTIVES: To determine the clinical and transcriptomic features of frequent exacerbators (FEs) and persistent FEs (PFEs) in the U-BIOPRED cohort.METHODS: We compared features of FE (≥2 exacerbations in past year) to infrequent exacerbators (IE, RESULTS: Of 317 patients, 62.4% had FE, of whom 63.6% had PFE, while 37.6% had IE, of whom 61.3% had PIE. Using multivariate analysis, FE was associated with short-acting beta-agonist use, sinusitis and daily oral corticosteroid use, while PFE was associated with eczema, short-acting beta-agonist use and asthma control index. CEA cell adhesion molecule 5 (CEACAM5) was the only differentially expressed transcript in bronchial biopsies between PE and IE. There were no differentially expressed genes in the other four compartments. There were higher expression scores for type 2, T-helper type-17 and type 1 pathway signatures together with those associated with viral infections in bronchial biopsies from FE compared to IE, while there were higher expression scores of type 2, type 1 and steroid insensitivity pathway signatures in bronchial biopsies of PFE compared to PIE.CONCLUSION: The FE group and its PFE subgroup are associated with poor asthma control while expressing higher type 1 and type 2 activation pathways compared to IE and PIE, respectively.

Published
2022

2. Mapping atopic dermatitis and anti-IL-22 response signatures to Type 2-low severe neutrophilic asthma

Author

Badi, Yusef Eamon, Pavel, Ana B, Pavlidis, Stelios, Riley, John H, Bates, Stewart, Kermani, Nazanin Zounemat, Knowles, Richard, Kolmert, Johan, Wheelock, Craig E, Worsley, Sally, Uddin, Mohib, Alving, Kjell, Bakke, Per S, Behndig, Annelie, Caruso, Massimo, Chanez, Pascal, Fleming, Louise J, Fowler, Stephen J, Frey, Urs, Howarth, Peter, Horváth, Ildikó, Krug, Norbert, Maitland-van der Zee, Anke H, Montuschi, Paolo, Roberts, Graham, Sanak, Marek, Shaw, Dominick E, Singer, Florian, Sterk, Peter J, Djukanovic, Ratko, Dahlen, Sven-Eric, Guo, Yi-Ke, Chung, Kian Fan, Guttman-Yassky, Emma, and Adcock, Ian M

Subjects
610 Medicine & health, 3. Good health
Abstract

BACKGROUND Transcriptomic changes in patients who respond clinically to biological therapies may identify responses in other tissues or diseases. OBJECTIVE To determine whether a disease signature identified in atopic dermatitis (AD) is seen in adults with severe asthma (SA) and whether a transcriptomic signature for AD patients who respond clinically to anti-IL-22 (Fezakinumab, FZ) is enriched in SA. METHODS An AD disease signature was obtained from analysis of differentially expressed genes (DEGs) between AD lesional and non-lesional skin biopsies. DEGs from lesional skin from therapeutic super-responders before and after 12 weeks FZ treatment defined the FZ-response signature. Gene Set Variation Analysis (GSVA) was used to produce enrichment scores (ES) of AD and FZ-response signatures in the U-BIOPRED asthma cohort. RESULTS The AD disease signature (112 up-regulated genes) encompassing inflammatory, T-cell, Th2 and Th17/Th22 pathways was enriched in the blood and sputum of asthmatics with increasing severity. Asthmatics with sputum neutrophilia and mixed granulocyte phenotypes were the most enriched (p

Catalog

Books, media, physical & digital resources
See catalog results